C4 Therapeutics, Inc. $CCCC

What the company doesAI summary of filing

C4 Therapeutics is a clinical-stage biopharmaceutical company that develops small-molecule protein degraders using its proprietary TORPEDO platform, which harnesses the body's natural protein destruction process. The company's lead programs include cemsidomide, an oral degrader targeting IKZF1/3 for multiple myeloma in Phase 2 development, and CFT8919, an oral degrader targeting mutant EGFR for non-small-cell lung cancer in Phase 1 development (being conducted by partner Betta Pharma in Greater China). C4 also has discovery-stage programs in inflammation, neuroinflammation, and neurodegeneration, and receives funding through collaborations with Merck KGaA, Roche, and Biogen. The company generates revenue through milestone payments and royalties from its partnership agreements but is pre-revenue from product sales. [10-K 2026-02-26]

Segments: Cemsidomide (IKZF1/3 degrader for multiple myeloma), CFT8919 (EGFR L858R degrader for non-small-cell lung cancer), Inflammation/neuroinflammation/neurodegeneration discovery programs, Merck KGaA and Roche collaboration programs